The device looks unassuming enough—a curved ultrasound transducer paired with what its makers call a "metalens," a personalized acoustic lens designed to thread sound waves through skull bone and into the deepest folds of the brain. But for SonoMind, the Paris-based medical device startup, it represents a $23.5 million wager that non-invasive brain stimulation could finally offer relief to patients for whom antidepressants and therapy have failed.
The company announced its Series A round on May 12, 2026, co-led by Critical Path Ventures and Bpifrance, the French public investment bank. The capital will fund multicenter clinical trials of SonoMind's ultrasound neuromodulation platform, a technology that targets subcortical brain circuits implicated in treatment-resistant depression—without surgery, without implants, and, the company hopes, without the side effects that have limited adoption of earlier brain stimulation methods.
It's an ambitious goal. Treatment-resistant depression, which affects roughly 30% to 50% of patients with major depressive disorder who cycle through medications without improvement, remains one of psychiatry's most stubborn challenges. Existing interventions—electroconvulsive therapy, transcranial magnetic stimulation, even the more experimental deep brain stimulation—work for some, but come with trade-offs. SonoMind's founders believe focused ultrasound could thread the needle: precise, repeatable, and tolerable enough for broader use.
Whether they're right remains to be seen. The company, founded in 2024 and employing 20 people as of May 2026, is moving from promising pilot data into the kind of rigorous, blinded, multicenter trials that will either validate the approach or expose its limits.
Two Decades in the Lab, Two Years on the Market
SonoMind didn't emerge from nowhere. The technology rests on roughly 25 years of ultrasound research at Physics for Medicine Paris, a joint laboratory of Inserm, ESPCI Paris-PSL, and CNRS. Scientific co-founders Mickaël Tanter and Jean-François Aubry, both veterans of that institution, spent years refining the physics of transcranial focused ultrasound—how to account for skull thickness, bone density variations, and the acoustic distortions that make targeting deep brain structures notoriously difficult.
CEO Jérémy Bercoff, the third co-founder, is handling the commercial side. His challenge: convince investors, regulators, and eventually clinicians that this approach deserves a place in psychiatric care.
The early clinical signal is intriguing, if preliminary. A 2025 pilot study at Hôpital Sainte-Anne in Paris, published in the journal Brain Stimulation, reported a reduction in symptom severity of more than 60% after just five consecutive days of treatment in patients with severe treatment-resistant depression. That's a striking number. It's also, importantly, from an open-label trial—meaning participants knew they were receiving active treatment, which introduces the possibility of placebo effects. The company is now designing randomized, double-blind, controlled studies to determine whether those results hold up under stricter conditions.
The early results warrant cautious optimism, though rigorous validation remains ahead. Low-intensity focused ultrasound, unlike electrical or magnetic stimulation, can reach structures like the cingulate cortex and subcallosal regions implicated in mood regulation without invasive procedures. Whether that translates to durable clinical benefit is the question SonoMind now has the funding to answer.
Regulatory Path and Timeline
SonoMind is aiming for market authorization around 2029, though the company hasn't yet disclosed which regulatory jurisdictions it will pursue first. Earlier reports from September 2025 suggested conversations with the FDA were planned, with the company considering a De Novo classification pathway—a route reserved for novel devices that don't have a predicate on the market. (For context, that's the same pathway used by some transcranial magnetic stimulation devices.)
The Series A follows a €3 million seed round raised in September 2025, split between €2 million in equity from Critical Path Ventures and €1 million in non-dilutive support from Bpifrance under the France 2030 deeptech initiative. Bpifrance's continued backing through both its French Tech Seed and Deep Tech 2030 funds signals sustained public sector interest in neuropsychiatric medical devices—an area where France has been actively trying to build national champions.
The company operates out of Paris, with support from Agoranov and Wilco, and maintains a presence at PariSanté Campus, a biomedical innovation hub in the city's 15th arrondissement. It picked up the France Biotech Trophée Medtech 2026 in March and the Prix Marcel Dassault pour l'innovation en psychiatrie last December—accolades that carry weight in French medtech circles, if not yet on the global stage.
The Bigger Bet
Perhaps the real story here isn't just one company or one device. It's the broader question of whether neuromodulation—after decades of niche use—can finally break into mainstream psychiatric care. SonoMind's ultrasound approach is part of a wave of non-invasive brain stimulation technologies vying for acceptance: TMS refinements, tDCS variations, and now focused ultrasound platforms targeting everything from depression to obsessive-compulsive disorder.
The science is maturing. The regulatory pathways are becoming clearer, if still arduous. What remains uncertain is whether healthcare systems, insurers, and clinicians will adopt these tools at scale—and whether patients who've exhausted pharmaceutical options will see them as genuine alternatives or expensive experiments.
SonoMind has the capital and the clinical pathway mapped out. The hard part, as always, is proving it works when no one knows which sound waves they're receiving.
